Inactive Instrument

Melinta Therapeutics, Inc.

Equities

Biotechnology & Medical Research

Melinta Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019

August 09, 2019 at 07:41 am EDT

Melinta Therapeutics, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced total revenue was USD 15.955 million compared to USD 12.022 million a year ago. Operating loss was USD 27.143 million compared to USD 49.726 million a year ago. Net loss was USD 36.180 million compared to USD 55.780 million a year ago. Basic loss per share was USD 3.07 compared to USD 6.92 a year ago. For the half year, total revenue was USD 30.039 million compared to USD 26.863 million a year ago. Operating loss was USD 51.729 million compared to USD 93.324 million a year ago. Net loss was USD 62.712 million compared to USD 85.212 million a year ago. Basic loss per share was USD 5.42 compared to USD 11.96 a year ago.

Latest news about Melinta Therapeutics, Inc.

Venatorx Pharmaceuticals and Melinta Therapeutics Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam	Feb. 23	CI
New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection	Feb. 20	CI
Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id	Dec. 05	CI
Melinta Therapeutics Announces Expanded Reimbursement and Access for REZZAYO (Rezafungin for Injection)	23-10-02	CI
Melinta Therapeutics Partners with BARDA to Advance Two FDA-Approved Antibiotics for Use in Pediatric Patients, and for Use Against Biothreat Pathogens	23-07-10	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO (Rezafungin for Injection) for the Treatment of Candidemia and Invasive Candidiasis	23-03-22	CI
Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis	23-01-25	CI
Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet	22-11-28	CI
Melinta Therapeutics, Inc. Acquires U.S. Rights to TOPROL-XL® (Metoprolol Succinate) from New American Therapeutics, Inc	22-04-06	CI
Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™	21-09-20	CI
Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)	21-07-07	CI
Melinta Therapeutics Announces Appointment of Jisoo Park as Head of Business Development, M&A and Strategy	21-07-06	CI
Melinta Therapeutics, Inc. Announces Appointment of Susan Blum as Chief Financial Officer. Effective July 1, 2021	21-06-29	CI
Melinta Therapeutics, LLC Appoints John Harlow as Chief Commercial Officer	21-03-29	CI
Melinta Therapeutics, LLC Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with Acute Bacterial Skin and Skin Structure Infections	21-03-15	CI
Melinta Therapeutics, LLC Appoints Kristen Allgor as Chief Human Resources Officer	20-11-16	CI
Melinta Therapeutics Announces Executive Changes	20-08-03	CI
Melinta Therapeutics Announces CEO Changes	20-08-03	CI
Melinta Therapeutics, Inc. cancelled the acquisition of Tetraphase Pharmaceuticals, Inc..	20-06-23	CI
Melinta Therapeutics, Inc. made a proposal to acquire Tetraphase Pharmaceuticals, Inc. for $13.1 million.	20-05-14	CI
Melinta Therapeutics, Inc. Emerged from Bankruptcy	20-04-20	CI
Second Modified First Amended Reorganization Plan Approved for Melinta Therapeutics, Inc.	20-04-11	CI
First Amended Disclosure Statement Approved for Melinta Therapeutics, Inc.	20-02-25	CI
First Amended Reorganization Plan and Disclosure Statement Filed by Melinta Therapeutics, Inc.	20-02-19	CI
Bidding Procedure Approved for Melinta Therapeutics, Inc.	20-02-11	CI

Chart Melinta Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Melinta Therapeutics Inc is a United States-based commercial-stage antibiotics company. The Company's products include Vabomere, Orbactiv, Minocin for injection, and Baxdela. Baxdela is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Vabomere is indicated for the treatment of patients over 18 years of age and older with complicated urinary tract infections (cUTI), including pyelonephritis. Orbactiv is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs). Minocin for injection is indicated for the treatment of infections due to susceptible isolates of designated microorganisms, including Acinetobacter species bacteria.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs